SCHEMBL7484970

SCHEMBL7484970

CC(C)C(CC(=O)N(C)CCOc1ccc(Cl)cc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ BLM P54132 1/20 0.45
▸ PMP22 Q01453 1/20 0.45
▸ PPARG P37231 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ FDPS P14324 1/20 0.42
▸ CASP1 P29466 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAOB P27338 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7497814 0.88 CYP1A2 (0.47) MEN1KMT2AHRH3CYP1A2CYP3A4
SCHEMBL7493044 0.79 TACR1 (0.42) PPARGPPARAFDPSALDH1A1RAB9A
SCHEMBL6946483 0.78 MEN1 (0.46) MEN1KMT2AHRH3CYP1A2CYP3A4
SCHEMBL21595882 0.78 HRH3 (0.58) MEN1KMT2AHRH3CYP1A2CYP3A4
SCHEMBL28417577 0.75 PPARG (0.55) MEN1KMT2ACYP1A2PPARGPPARA
SCHEMBL7484977 0.75 CASP1 (0.50) MEN1KMT2ACASP1SMN1; SMN2L3MBTL1
SCHEMBL7488762 0.72 HRH3 (0.44) MEN1KMT2AHRH3CYP1A2CYP3A4
SCHEMBL10829126 0.72 LTA4H (0.54) MEN1KMT2AHRH3CYP1A2CYP3A4
SCHEMBL7080512 0.72 PPARA (0.44) MEN1KMT2AHRH3CYP1A2CYP3A4
SCHEMBL8778563 0.72 HRH3 (0.49) MEN1KMT2AHRH3CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6462042-B1 TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITORS; INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, CANCER, CARDIO-VASCULAR DISEASES, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPOROSIS, NEURODEGENERATION, ALZHEIMER'S DISEASE, STROKE DARWIN DISCOVERY LIMITED (GB) 2002-10-08 — — US disclosed
EP-1237867-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS Darwin Discovery Limited (GB) 2002-09-11 — — EP disclosed
WO-2001044188-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS DARWIN DISCOVERY LIMITED (GB) 2001-06-21 — — WO disclosed
Send feedback